Limits...
Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series.

Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, Tu SM - Case Rep Oncol Med (2015)

Bottom Line: Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality.Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap.Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.

View Article: PubMed Central - PubMed

Affiliation: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ABSTRACT
Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality. Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap. We propose a maintenance regimen with metformin and/or Zyflamend that targets cancer stem cells and the tumor microenvironment to keep the cancer dormant and prevent it from activation from dormancy. Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.

No MeSH data available.


Related in: MedlinePlus

CT of the abdomen in case #3 revealed liver metastases (a) before the treatment and (b) after 17 months of treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4377453&req=5

fig2: CT of the abdomen in case #3 revealed liver metastases (a) before the treatment and (b) after 17 months of treatment.

Mentions: Case 3 was a 64-year-old white man who was diagnosed with prostate cancer in August 2007. His PSA was 93, his Gleason score was 9 (4 + 5), and he had pelvic lymphadenopathy at diagnosis. He received chemohormonal ablative therapy with weekly docetaxel at 25 mg/m2 followed by radical prostatectomy in September 2009. His pathological disease stage was T3aN0, and his surgical margins were negative. In November 2012, he developed recurrent lymphadenopathy and resumed hormone ablative therapy. In March 2013, he developed florid metastases in the liver, bone, lymph nodes, and bladder. Although his symptoms improved and his liver metastases and bladder lesions shrank, his PSA level continued to increase from 6.7 to 34.0 after 8 courses of salvage chemotherapy comprising cabazitaxel and carboplatin. In August 2013, metformin 500 mg orally twice daily was added to the chemotherapy regimen. Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)). CT findings of liver metastases and response to treatment are shown in Figure 2.


Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series.

Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, Tu SM - Case Rep Oncol Med (2015)

CT of the abdomen in case #3 revealed liver metastases (a) before the treatment and (b) after 17 months of treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4377453&req=5

fig2: CT of the abdomen in case #3 revealed liver metastases (a) before the treatment and (b) after 17 months of treatment.
Mentions: Case 3 was a 64-year-old white man who was diagnosed with prostate cancer in August 2007. His PSA was 93, his Gleason score was 9 (4 + 5), and he had pelvic lymphadenopathy at diagnosis. He received chemohormonal ablative therapy with weekly docetaxel at 25 mg/m2 followed by radical prostatectomy in September 2009. His pathological disease stage was T3aN0, and his surgical margins were negative. In November 2012, he developed recurrent lymphadenopathy and resumed hormone ablative therapy. In March 2013, he developed florid metastases in the liver, bone, lymph nodes, and bladder. Although his symptoms improved and his liver metastases and bladder lesions shrank, his PSA level continued to increase from 6.7 to 34.0 after 8 courses of salvage chemotherapy comprising cabazitaxel and carboplatin. In August 2013, metformin 500 mg orally twice daily was added to the chemotherapy regimen. Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)). CT findings of liver metastases and response to treatment are shown in Figure 2.

Bottom Line: Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality.Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap.Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.

View Article: PubMed Central - PubMed

Affiliation: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ABSTRACT
Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality. Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap. We propose a maintenance regimen with metformin and/or Zyflamend that targets cancer stem cells and the tumor microenvironment to keep the cancer dormant and prevent it from activation from dormancy. Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.

No MeSH data available.


Related in: MedlinePlus